351 related articles for article (PubMed ID: 35109899)
1. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.
Merkens L; Sailer V; Lessel D; Janzen E; Greimeier S; Kirfel J; Perner S; Pantel K; Werner S; von Amsberg G
J Exp Clin Cancer Res; 2022 Feb; 41(1):46. PubMed ID: 35109899
[TBL] [Abstract][Full Text] [Related]
2. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
4. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
6. The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.
Pernicová Z; Slabáková E; Fedr R; Šimečková Š; Jaroš J; Suchánková T; Bouchal J; Kharaishvili G; Král M; Kozubík A; Souček K
Mol Cancer; 2014 May; 13():113. PubMed ID: 24884804
[TBL] [Abstract][Full Text] [Related]
7. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
8. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.
Terry S; Maillé P; Baaddi H; Kheuang L; Soyeux P; Nicolaiew N; Ceraline J; Firlej V; Beltran H; Allory Y; de la Taille A; Vacherot F
Neoplasia; 2013 Jul; 15(7):761-72. PubMed ID: 23814488
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation.
Frigo DE; McDonnell DP
Mol Cancer Ther; 2008 Mar; 7(3):659-69. PubMed ID: 18347151
[TBL] [Abstract][Full Text] [Related]
10. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer.
Akoto T; Bhagirath D; Saini S
Cancer Drug Resist; 2020; 3(4):804-818. PubMed ID: 33426506
[TBL] [Abstract][Full Text] [Related]
12. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
Fernandes RC; Toubia J; Townley S; Hanson AR; Dredge BK; Pillman KA; Bert AG; Winter JM; Iggo R; Das R; Obinata D; ; Sandhu S; Risbridger GP; Taylor RA; Lawrence MG; Butler LM; Zoubeidi A; Gregory PA; Tilley WD; Hickey TE; Goodall GJ; Selth LA
Cell Rep; 2021 Jan; 34(1):108585. PubMed ID: 33406413
[TBL] [Abstract][Full Text] [Related]
13. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
[TBL] [Abstract][Full Text] [Related]
14. Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients.
Bhagirath D; Dahiya R; Majid S; Tabatabai ZL; Saini S
J Vis Exp; 2019 Nov; (153):. PubMed ID: 31814621
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Signaling and the Emergence of Lethal Neuroendocrine Prostate Cancer With the Treatment-Induced Suppression of the Androgen Receptor: A Literature Review.
Dhavale M; Abdelaal MK; Alam ABMN; Blazin T; Mohammed LM; Prajapati D; Ballestas NP; Mostafa JA
Cureus; 2021 Feb; 13(2):e13402. PubMed ID: 33754118
[TBL] [Abstract][Full Text] [Related]
16. Monoamine oxidase A drives neuroendocrine differentiation in prostate cancer.
Shui X; Ren X; Xu R; Xie Q; Hu Y; Qin J; Meng H; Zhang C; Zhao J; Shi C
Biochem Biophys Res Commun; 2022 May; 606():135-141. PubMed ID: 35349822
[TBL] [Abstract][Full Text] [Related]
17. Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
Zhu S; Tian H; Niu X; Wang J; Li X; Jiang N; Wen S; Chen X; Ren S; Xu C; Chang C; Flores-Morales A; Shang Z; Sun Y; Niu Y
Oncogene; 2019 Jun; 38(24):4875-4884. PubMed ID: 30770901
[TBL] [Abstract][Full Text] [Related]
18. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
Weissenrieder JS; Reilly JE; Neighbors JD; Hohl RJ
Prostate; 2019 Jan; 79(1):21-30. PubMed ID: 30106164
[TBL] [Abstract][Full Text] [Related]
20. Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review.
Kouroukli O; Bravou V; Giannitsas K; Tzelepi V
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]